Complement deficiency

Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Pharmaceutical, Health, Complement deficiency, Organ systems, Medical specialties, Angioedema, Catabasis Pharmaceuticals, Hereditary angioedema, Clinical medicine, Kinin–kallikrein system, Hae, QLS, Kallikrein

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET.

Key Points: 
  • Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET.
  • The session entitled HAE There- Development Landscape in Hereditary Angioedema (HAE) will include an overview of the HAE treatment landscape, information about Catabasiss lead program QLS-215, and a Q&A session.
  • At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases.
  • Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience

Retrieved on: 
Tuesday, August 3, 2021
Complement deficiency, Organ systems, Medical specialties, Hereditary angioedema, Serpinopathies, Clinical medicine, C1-inhibitor, Angioedema, CSL Behring, Hae

"Regardless of being on a preventive therapy or not, being prepared to rapidly treat an HAE attack is of utmost importance.

Key Points: 
  • "Regardless of being on a preventive therapy or not, being prepared to rapidly treat an HAE attack is of utmost importance.
  • BERINERT is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) attacks in adult and pediatric patients.
  • CSL Behring has marketed its C1 Esterase Inhibitor concentrate, BERINERT, in Germany for more than 30 years.
  • Serious arterial and venous thromboembolic (TE) events have been reported following administration of recommended doses of C1 Esterase Inhibitor (Human) products to patients with HAE.

BioCryst Appoints Vincent Milano to Board of Directors

Retrieved on: 
Wednesday, July 28, 2021
Life sciences, Biotechnology, Industry economics), Complement deficiency, BioCryst Pharmaceuticals, Hereditary angioedema, ViroPharma, Angioedema, Hae, Small molecule

RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors.
  • Prior to joining ViroPharma in 1996, he served as a senior manager at KPMG LLP, an independent registered public accounting firm.
  • Mr. Milano currently serves on the boards of directors of Idera Pharmaceuticals, Aclaris Therapeutics and VenatoRx Pharmaceuticals, and is the chairman of the board for Life Science Cares Philadelphia.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.

Global Hereditary Angioedema Clinical Trial Pipeline Research Report-2025: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Pharmaceutical, Genetics, Health, Clinical trials, Health sciences, Complement deficiency, Health, Life sciences, Drug discovery, Clinical research, Pharmaceutical industry, Design of experiments, Hereditary angioedema, Clinical trial, Angioedema, BioCryst Pharmaceuticals

The "Global Hereditary Angioedema Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hereditary Angioedema Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Hereditary Angioedema Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Hereditary Angioedema market.
  • It covers emerging therapies for Hereditary Angioedema in active clinical development stages including early and late stage clinical trials.
  • The report provides Hereditary Angioedema pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

Retrieved on: 
Monday, July 12, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Complement deficiency, Organ systems, Hereditary angioedema, Serpinopathies, Medical specialties, Angioedema, Hae, Clinical medicine, Orphan drugs

As KVD900 halted attack progression and resolved attacks more quickly in patients with HAE, while demonstrating a good safety and tolerability profile, it could be a valued choice for physicians and patients in managing HAE.

Key Points: 
  • As KVD900 halted attack progression and resolved attacks more quickly in patients with HAE, while demonstrating a good safety and tolerability profile, it could be a valued choice for physicians and patients in managing HAE.
  • The late-breaking poster, titled A single on-demand treatment with orally administered KVD900 significantly slows progression and accelerates resolution of attacks in patients with hereditary angioedema (HAE): results of a phase 2, placebo-controlled, double-blind cross-over trial, contains the comprehensive data set from the companys Phase 2 clinical trial of KVD900 in HAE patients.
  • KalVista presented four other posters at EAACI related to the HAE clinical landscape and unmet needs, as well as preclinical data from other oral molecules.
  • Patients with nC1-HAE may represent a more sizeable population of patients with HAE in the U.S. than previously suspected.

New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress

Retrieved on: 
Saturday, July 10, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Complement deficiency, Organ systems, Medical specialties, Drugs, Lanadelumab, Angioedema, Hereditary angioedema, Hae, The HELP Study™ Open-label Extension, Hereditary Angioedema, TAKHZYRO® (lanadelumab), Takeda Pharmaceutical Company Limited, THE HELP STUDY™ OPEN-LABEL EXTENSION, HEREDITARY ANGIOEDEMA, TAKHZYRO® (LANADELUMAB), TAKEDA PHARMACEUTICAL COMPANY LIMITED

TAKHZYRO, which has a half-life of approximately 14 days, is expected to reach steady state at approximately 70 days.

Key Points: 
  • TAKHZYRO, which has a half-life of approximately 14 days, is expected to reach steady state at approximately 70 days.
  • These analyses further assert the important role TAKHZYRO can play in the lives of people who live with HAE.
  • The HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE) is an evaluation of the long-term efficacy and safety of TAKHZYRO in hereditary angioedema (HAE) patients of at least 12 years of age and older.
  • Rollover patients received a dose of 300 mg TAKHZYRO on Day 0 and then every two weeks after their first attack.

Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference

Retrieved on: 
Wednesday, July 7, 2021
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Life sciences, Medical specialties, Clinical medicine, Complement deficiency, Biotechnology, Catabasis Pharmaceuticals, Angioedema, Kinin–kallikrein system, Hereditary angioedema, Kallikrein, Monoclonal antibody, Biopharmaceutical

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference.

Key Points: 
  • Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference.
  • The presentation will take place on Tuesday, July 13th, 2021 at 12:30pm ET.
  • At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases.
  • Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

Retrieved on: 
Thursday, July 1, 2021
Complement deficiency, Medical specialties, Organ systems, Drug eruptions, Branches of biology, Angioedema, Hereditary angioedema, Bradykinin, European Academy of Allergy and Clinical Immunology, Jerini, Icatibant

ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, to be held virtually July 10-16, 2021.

Key Points: 
  • ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, to be held virtually July 10-16, 2021.
  • The virtual poster presentation will be on the EAACI website from July 10-16, 2021, and will be also accessible through the Investors page on the companys website at www.pharvaris.com .
  • Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients.
  • These forward-looking statements should not be relied upon as representing Pharvaris views as of any date subsequent to the date of this press release.

KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)

Retrieved on: 
Monday, June 28, 2021
Biotechnology, Pharmaceutical, Health, Complement deficiency, Organ systems, Medical specialties, Clinical medicine, Kinin–kallikrein system, Angioedema, Kallikrein, Hereditary angioedema, Macular edema, European Academy of Allergy and Clinical Immunology, Plasma kallikrein

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of multiple abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress, from July 10-12, 2021.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of multiple abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress, from July 10-12, 2021.
  • KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
  • KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints.
  • In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

Pharvaris Announces Annual Meeting of Shareholders

Retrieved on: 
Friday, June 11, 2021
Complement deficiency, Organ systems, Drug eruptions, Hereditary angioedema, Serpinopathies, Branches of biology, Medical specialties, Bradykinin, Angioedema, B2, Jerini

ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the annual general meeting of shareholders will take place on Tuesday, June 29, 2021 at 1:00 p.m. CEST (7:00 a.m. EDT).

Key Points: 
  • ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the annual general meeting of shareholders will take place on Tuesday, June 29, 2021 at 1:00 p.m. CEST (7:00 a.m. EDT).
  • All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the Investors section of Pharvaris website under Events & Presentations.
  • Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting.
  • Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients.